PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
29577550-1	2018	AIMS: Methionine aminopeptidase 2 (MetAP2) inhibition has been shown to result in significant weight loss and improved glucose control.	Glucose	119-126	methionyl aminopeptidase 2	Homo sapiens	6-33	
32077231-0	2020	The methionine aminopeptidase 2 inhibitor ZGN-1061 improves glucose control and weight in overweight and obese individuals with type 2 diabetes: a randomized placebo-controlled trial.	Glucose	60-67	methionyl aminopeptidase 2	Homo sapiens	4-31	
32077231-1	2020	The methionine aminopeptidase 2 (MetAP2) inhibitor ZGN-1061 lowered weight and improved glucose in preclinical studies.	Glucose	88-95	methionyl aminopeptidase 2	Homo sapiens	4-31	
32077231-1	2020	The methionine aminopeptidase 2 (MetAP2) inhibitor ZGN-1061 lowered weight and improved glucose in preclinical studies.	Glucose	88-95	methionyl aminopeptidase 2	Homo sapiens	33-39	
32077231-8	2020	We conclude that MetAP2 inhibition with ZGN-1061 for 12 weeks improved glucose control and aided weight loss in overweight and obese people with type 2 diabetes.	Glucose	71-78	methionyl aminopeptidase 2	Homo sapiens	17-23	
31264515-0	2019	A MetAP2 inhibitor blocks adipogenesis, yet improves glucose uptake in cells.	Glucose	53-60	methionyl aminopeptidase 2	Homo sapiens	2-8	
29577550-1	2018	AIMS: Methionine aminopeptidase 2 (MetAP2) inhibition has been shown to result in significant weight loss and improved glucose control.	Glucose	119-126	methionyl aminopeptidase 2	Homo sapiens	35-41